A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)

被引：0

作者：

Vyas, Paresh ^{[1
,2
,3
,4
]}

Daver, Naval ^{[5
]}

Chao, Mark ^{[6
]}

Xing, Guan ^{[6
]}

Renard, Camille ^{[6
]}

Ramsingh, Giri ^{[6
]}

Sallman, David ^{[7
]}

机构：

[1] Weatherall Inst Mol Med, MRC Mol Hematol Unit, Oxford, England

[2] Univ Oxford, MRC Mol Haematol Unit, Oxford, England

[3] Univ Oxford, Oxford Biomed Res Ctr, Oxford, England

[4] Oxford Univ Hosp, Oxford, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[6] Gilead Sci Inc, Foster City, CA USA

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

关键词：

AML; acute myeloid leukemia; magrolimab; azacitidine; venetoclax; CD47; Trial-in-Progress;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-399

引用

页码：S247 / S247

页数：1